NWRN — Newron Pharmaceuticals SpA Balance Sheet
0.000.00%
Last trade - 00:00
- CH₣135.64m
- CH₣170.69m
- €9.06m
C2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Interim Report | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 39.2 | 31.3 | 34.6 | 22.8 | 12.6 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 5.01 | 5.76 | 4.05 | 4.97 | 5.18 |
Prepaid Expenses | |||||
Total Current Assets | 45.5 | 37.9 | 39.4 | 28.5 | 19.7 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.252 | 0.734 | 0.577 | 0.527 | 0.405 |
Net Intangible Assets | |||||
Long Term Notes Receivable | |||||
Total Assets | 60.3 | 51.2 | 50.5 | 37.2 | 25.9 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 5.59 | 6.89 | 3.65 | 5.04 | 28.9 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 23.5 | 34 | 47.4 | 51.2 | 55.8 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 36.8 | 17.2 | 3.11 | -14 | -29.9 |
Total Liabilities & Shareholders' Equity | 60.3 | 51.2 | 50.5 | 37.2 | 25.9 |
Total Common Shares Outstanding |